Sofia M. Calado

Dr. Sofia M. Calado

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Ophthalmology
Verified
Journal Article
Closed access
BMBénédicte MJ Merle
Bénédicte MJ Merle
JCJohanna M. Colijn
Johanna M. Colijn
ACAudrey Cougnard-Grégoire
Audrey Cougnard-Grégoire
Alexandra P.M. de Koning-BackusAlexandra P.M. de Koning-Backus
Alexandra P.M. de Koning-Backus
MDMarie-Noëlle Delyfer
Marie-Noëlle Delyfer
VVVassil Vasiliev
Vassil Vasiliev

1 March 2019 in Ophthalmology
Verified
Journal Article
Open access
JCJohanna M. Colijn
Johanna M. Colijn
AHAnneke I. Den Hollander
Anneke I. Den Hollander
Ayse DemirkanAyse Demirkan
Ayse Demirkan
ACAudrey Cougnard-Grégoire
Audrey Cougnard-Grégoire
TVTimo Verzijden
Timo Verzijden
MZMarkus Zumbansen
Markus Zumbansen
Genetic and epidemiologic studies have shown that lipid genes and high-density lipoproteins (HDLs) are implicated in age-related macular degeneration (AMD). We studied circulating lipid levels in relationship to AMD in a large European dataset. Pooled analysis of cross-sectional data. Individuals (N = 30 953) aged 50 years or older participating in the European Eye Epidemiology (E3) consortium and 1530 individuals from the Rotterdam Study with lipid subfraction data. AMD features were graded on fundus photographs using the Rotterdam classification. Routine blood lipid measurements, genetics, medication, and potential confounders were extracted from the E3 database. In a subgroup of the Rotterdam Study, lipid subfractions were identified by the Nightingale biomarker platform. Random-intercepts mixed-effects models incorporating confounders and study site as a random effect were used to estimate associations. AMD features and stage; lipid measurements. HDL was associated with an increased risk of AMD (odds ratio [OR], 1.21 per 1-mmol/l increase; 95% confidence interval [CI], 1.14-1.29), whereas triglycerides were associated with a decreased risk (OR, 0.94 per 1-mmol/l increase; 95% CI, 0.91-0.97). Both were associated with drusen size. Higher HDL raised the odds of larger drusen, whereas higher triglycerides decreases the odds. LDL cholesterol reached statistical significance only in the association with early AMD (P = 0.045). Regarding lipid subfractions, the concentration of extra-large HDL particles showed the most prominent association with AMD (OR, 1.24; 95% CI, 1.10-1.40). The cholesteryl ester transfer protein risk variant (rs17231506) for AMD was in line with increased HDL levels (P = 7.7 × 10-7), but lipase C risk variants (rs2043085, rs2070895) were associated in an opposite way (P = 1.0 × 10-6 and P = 1.6 × 10-4). Our study suggested that HDL cholesterol is associated with increased risk of AMD and that triglycerides are negatively associated. Both show the strongest association with early AMD and drusen. Extra-large HDL subfractions seem to be drivers in the relationship with AMD, and variants in lipid genes play a more ambiguous role in this association. Whether systemic lipids directly influence AMD or represent lipid metabolism in the retina remains to be answered.

31 December 2019 in Molecular Medicine
Verified
Journal Article
Open access
PDF file
LVLourdes Valdés-Sánchez
Lourdes Valdés-Sánchez
SCSofia M. Calado
Sofia M. Calado
BCBerta de la Cerda
Berta de la Cerda
AAAna Aramburu
Ana Aramburu
AGAna Belén García-Delgado
Ana Belén García-Delgado
Francisco J. Diaz CorralesFrancisco J. Diaz Corrales
Francisco J. Diaz Corrales
Background: Mutations in pre-mRNA splicing factorPRPF31can lead to retinitis pigmentosa (RP). Although the exact disease mechanism remains unknown, it has been hypothesized that haploinsufficiency might be involved in the pathophysiology of the disease.Methods: In this study, we have analyzed a mouse model containing the p.A216P mutation inPrpf31gene.Results: We found that mutant Prpf31 protein produces cytoplasmic aggregates in the retinal pigment epithelium and decreasing the protein levels of this splicing factor in the nucleus. Additionally, normal protein was recruited in insoluble aggregates when the mutant protein was overexpressed in vitro. In response to protein aggregation,Hspa4lis overexpressed. This member of the HSP70 family of chaperones might contribute to the correct folding and solubilization of the mutant protein, allowing its translocation to the nucleus.Conclusions: Our data suggests that a mechanism haploinsufficiency and dominant-negative is involved in retinal degeneration due to mutations inPRPF31.HSP70 over-expression might be a new therapeutic target for the treatment of retinal degeneration due toPRPF31mutations.

27 June 2023 in Cells
Verified
Journal Article
Open access
PDF file
CCCátia Dias Correia
Cátia Dias Correia
AFAnita Ferreira
Anita Ferreira
Mónica Alexandra Teotónio FernandesMónica Alexandra Teotónio Fernandes
Mónica Alexandra Teotónio Fernandes
BSBarbara Sofia Marques da Silva
Barbara Sofia Marques da Silva
FEFilipa Esteves
Filipa Esteves
SCSofia M. Calado
Sofia M. Calado
Cardiovascular diseases (CVDs) are pointed out by the World Health Organization (WHO) as the leading cause of death, contributing to a significant and growing global health and economic burden. Despite advancements in clinical approaches, there is a critical need for innovative cardiovascular treatments to improve patient outcomes. Therapies based on adult stem cells (ASCs) and embryonic stem cells (ESCs) have emerged as promising strategies to regenerate damaged cardiac tissue and restore cardiac function. Moreover, the generation of human induced pluripotent stem cells (iPSCs) from somatic cells has opened new avenues for disease modeling, drug discovery, and regenerative medicine applications, with fewer ethical concerns than those associated with ESCs. Herein, we provide a state-of-the-art review on the application of human pluripotent stem cells in CVD research and clinics. We describe the types and sources of stem cells that have been tested in preclinical and clinical trials for the treatment of CVDs as well as the applications of pluripotent stem-cell-derived in vitro systems to mimic disease phenotypes. How human stem-cell-based in vitro systems can overcome the limitations of current toxicological studies is also discussed. Finally, the current state of clinical trials involving stem-cell-based approaches to treat CVDs are presented, and the strengths and weaknesses are critically discussed to assess whether researchers and clinicians are getting closer to success.

24 May 2020 in World Journal of Clinical Oncology
Verified
Journal Article
Open access
Mónica Alexandra Teotónio FernandesMónica Alexandra Teotónio Fernandes
Mónica Alexandra Teotónio Fernandes
SCSofia M. Calado
Sofia M. Calado
LMLeonardo Mendes-Silva
Leonardo Mendes-Silva
José BragançaJosé Bragança
José Bragança
CITED2 and the modulation of the hypoxic response in cancer

1 April 2016 in Human Gene Therapy Methods
Verified
Journal Article
Closed access
SCSofia M. Calado
Sofia M. Calado
Francisco J. Diaz CorralesFrancisco J. Diaz Corrales
Francisco J. Diaz Corrales
GSGabriela Silva
Gabriela Silva
Diabetic retinopathy (DR) is one of the major complications of Diabetes mellitus. It is characterized by retinal microvascular changes caused by chronic exposure to hyperglycemia, leading to low tissue oxygenation and ultimately to neovascularization. Laser photocoagulation and vitrectomy are the most efficient treatments for DR, but display severe side effects such as the destruction of the healthy retina. Another clinical approach uses anti-angiogenic agents to prevent and delay progression of neovascularization, but these require recurrent local administrations which increase the possibility of retinal detachment, vitreous hemorrhage, and cataract formation. Studies in human diabetic retinas have revealed an imbalance between pro-angiogenic factors such as the vascular endothelial growth factor (VEGF) and anti-angiogenic factors, like pigment epithelial-derived factor (PEDF). This imbalance favors pathological angiogenesis contributing to DR, and can constitute a therapeutic target. Gene therapy was recently shown to be an adequate intervention for long-term treatment of several retinal pathologies. We have previously shown the newly engineered episomal vector pEPito to be able of sustained gene expression in the mouse retina. We here show that pEPito was able to overexpress PEDF for up to three months, both in in vitro cultures of human RPE cells, as well as in the retina of diabetic mice after a single subretinal injection. In vivo, in parallel with the increase in PEDF we observed a decrease in VEGF levels in injected compared with non-injected eyes and a significant effect on two hallmarks of DR: reduction of glucose transport (by glucose transporter GLUT1), and reduction of inflammation by decreased reactivity of microglia. Jointly, these results point to a significant therapeutic potential of gene therapy with pEPito-PEDF for the treatment of DR.